期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 36, 期 9, 页码 568-578出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2015.05.007
关键词
cystathionine gamma-lyase; endothelium-derived hyperpolarizing factor; gasotransmitters; heme oxygenase-1; hydrogen sulfide; nitric oxide
资金
- Discovery Grant from the Natural Sciences and Engineering Research Council of Canada (NSERC)
- American Diabetes Association
- US National Institutes of Health (NIH)
- Shriners Hospitals for Children
- NIH
- UK Medical Research Council (MEC)
- British Heart Foundation [RG/09/001/25940]
- MRC [G0700288]
- Royal Society
- European Commission
- Aristeia grant [1436]
- European Commission (ESF)
- Greek national funds through the Operational Program 'Education and Lifelong Learning'
- COST (Cooperation in Science and Technology) Action [BM1005]
- MRC [MR/M022706/1, G0700288, MR/L01985X/1, G0701824] Funding Source: UKRI
- British Heart Foundation [RG/09/001/25940] Funding Source: researchfish
- Medical Research Council [G0700288, MR/L01985X/1, G0701824, MR/M022706/1] Funding Source: researchfish
Endothelial dysfunction (EDF) reflects pathophysiological changes in the phenotype and functions of endothelial cells that result from and/or contribute to a plethora of cardiovascular diseases. We review the role of hydrogen sulfide (H2S) in the pathogenesis of EDF, one of the fastest advancing research topics. Conventionally treated as an environment pollutant, H2S is also produced in endothelial cells and participates in the fine regulation of endothelial integrity and functions. Disturbed H2S bioavailability has been suggested to be a novel indicator of EDF progress and prognosis. EDF manifests in different forms in multiple pathologies, but therapeutics aimed at remedying altered H2S bioavailability may benefit all.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
